The 12th Symposium on Prostate Cancer  
Clark Atlanta University  
September 16-19, 2018

SAMPLE ABSTRACT FORM  
E-mail completed abstracts in Microsoft Word format to: Ms. Cheryl Croft  
crtd@cau.edu

(Read all of the instructions carefully before preparing your abstract.)

1. Abstract submissions should not exceed the box below.
2. Font size should be 12 points, Times New Roman with Justify Alignment.
3. Title of abstract should be in caps.
4. Name of presenting author should be in bold and underlined.
5. Poster boards are sized at 48 width x 36 height (ft.)
6. Abstract should not exceed 325 words.

Deadline for Abstracts: June 15, 2018

If you do not receive a confirmation of receipt for your abstract within 1 week, please contact Ms. Croft directly: ccroft@cau.edu; 404-880-6741 office

EFFECTS OF TGF-β ON SURVIVAL OF SELECTED PROSTATE CANCER CELLS
Ralph Baffoe, Mojgan Zavareh, Ana Cecilia Millena and Shafiq Khan, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, Georgia.

In the normal prostate, organ steady state is achieved by a balance between the rate of cell proliferation and the rate of apoptosis. This equilibrium is primarily regulated by androgens. It is also known that growth factors contribute to this equilibrium by autocrine production and then regulate cell response to its growth inhibitory and apoptotic effects. TGF-β is a growth factor known to elicit a growth inhibitory effect in the normal and benign prostate cells but induces cell proliferation in malignant cells. However, little is known on its effects on apoptosis and its regulation. The objective of the study is to determine if TGF-β can induce apoptosis in prostate cancer cells and use DAPI (4′-6-diamidino-2-phenylindole) staining as the procedure to measure apoptosis index. In this study, prostate cell lines DU145, PC3 and C-33 were treated with two doses of TGF-β (1 and 10 ng/ml) for 72 hours. After treatment, cells were fixed and stained with DAPI to visualize the cells under UV light. Apoptosis was determined if there was visible fragmented nuclei/condensed chromatin. PI-3 kinase and MAP kinase inhibitors, LY294002 and PD 98059 respectively, were used as positive controls for apoptosis. Among the four cell lines, DU145 and C-33 showed significant level of cell death (up to 50%) when treated with the higher dose of TGF-β (10 ng/ml). PC3 cells were more sensitive to the lower dose of TGF-β (1ng/ml) showing 38% apoptotic cells. LY and PD inhibitors induced apoptosis in DU145 (LY 78%, PD 56%), PC3 (LY 38%, PD 21%), and C33 (LY 40%, PD 26%). Based on the results, we were able to demonstrate that TGF-β can induce apoptosis in these cells and that apoptosis can be measured using DAPI staining. Some minor technical difficulties were encountered such as length of treatment and normalized cell number. These observations will be considered in the next set of experiments.

Acknowledgements: These studies were supported by the NIH/NIMHD/RCMI Grant #5 G12 MD007590 and NIH/NIMHD/P20 Grant #2P20MD002285.